Dartmouth Health Continuing Education for Professionals Home, Medicine Grand Rounds - Neuro-Axis on Fire:Â Checkpoint Inhibitor Neuritis / Encephalitis and CAR-T Neurotoxicity. How fast can it burn?, 12/18/2020 8:00:00 AM - 12/18/2023 9:00:00 AM, Dr. Chan describes the clinical syndromes and neurologic presentations of complications of checkpoint inhibitor and CAR-T therapies. She summarizes diagnostic criteria, grading systems and current pathophysiologic understanding for symptoms of encephalitis, myasthenia gravis, Guillaume-Barre Syndrome and immune effector cell-associated neurotoxicity syndrome related to CAR-T, as well as consensus management guidelines and prognosis.
Presenter
Amy M. Chan, MD
Assistant Professor of Medicine
Geisel School of Medicine at Dartmouth
Section of Medical Oncology
Dartmouth-Hitchcock Medical Center
About our presenter:
Dr. Chan earned a BS in Engineering from Duke University and an MS in Engineering from Stanford University. She received her MD with honors from Geisel School of Medicine at Dartmouth and completed her training in Neurology and fellowship in Neuro-Oncology at Yale-New Haven Hospital. She is a certified adult Neuro-Oncologist, specializing in the treatment of adult patients with glioblastoma, CNS lymphoma, rare nervous system tumors including malignant peripheral nerve sheath tumor, and neurologic complications of systemic cancer and its treatment. She is a clinician at heart and continues to work on bedside evaluation of clinical neurologic manifestations to gain new insights into the effects of emerging therapeutics.
Learning Outcome(s)
Participants will be able to describe the diagnosis, grading system and management of complications of checkpoint inhibitor and CAR-T therapies.
Disclosure
In accordance with the disclosure policy of Dartmouth-Hitchcock/Geisel School of Medicine at Dartmouth as well as standards set forth by the Accreditation Council on Continuing Medical Education and the Nursing Continuing Education Council standards set forth by the American Nurses Credentialing Center Commission on Accreditation, continuing medical education and nursing education activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content have been asked to disclose any financial relationship* they have to a commercial interest (any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients). Such disclosure is not intended to suggest or condone bias in any presentation, but is elicited to provide participants with information that might be of potential importance to their evaluation of a given activity.
The following Activity Physician Director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content have reported the following financial interest or relationship* with various companies/organizations. The Activity Director and Planning Committee member roles were resolved by altering the individual™s control over content about the products or services of the commercial interest by the Associate Dean for CME and the Department of Medicine Chair. All potential conflict(s) were resolved.
* Kelly Kieffer, MD ~ her spouse is a consultant for OcculoBio.
* Richard I. Rothstein, MD ~ has research support from Baranova (research grant to Dartmouth-Hitchcock Medical Center) and is on the Scientific Advisory Board for Allurion.
Other planning committee member(s), speaker(s), activity director(s), author(s) or anyone in a position to control the content for this program report no financial interest or relationship* with any company(ies) or organizations whose product may be germane to the content of their presentations.
*A financial interest or relationship" refers to an equity position, receipt of royalties, consultantship, funding by a research grant, receiving honoraria for educational services elsewhere, or to any other relationship to a company that provides sufficient reason for disclosure, in keeping with the spirit of the stated policy.
Bibliographic Material
See presentation for bibliographic sources to allow for further study.
Presenter
Amy M. Chan, MD
Assistant Professor of Medicine
Geisel School of Medicine at Dartmouth
Section of Medical Oncology
Dartmouth-Hitchcock Medical Center
About our presenter:
Dr. Chan earned a BS in Engineering from Duke University and an MS in Engineering from Stanford University. She received her MD with honors from Geisel School of Medicine at Dartmouth and completed her training in Neurology and fellowship in Neuro-Oncology at Yale-New Haven Hospital. She is a certified adult Neuro-Oncologist, specializing in the treatment of adult patients with glioblastoma, CNS lymphoma, rare nervous system tumors including malignant peripheral nerve sheath tumor, and neurologic complications of systemic cancer and its treatment. She is a clinician at heart and continues to work on bedside evaluation of clinical neurologic manifestations to gain new insights into the effects of emerging therapeutics.
Learning Outcome(s)
Participants will be able to describe the diagnosis, grading system and management of complications of checkpoint inhibitor and CAR-T therapies.
Disclosure
In accordance with the disclosure policy of Dartmouth-Hitchcock/Geisel School of Medicine at Dartmouth as well as standards set forth by the Accreditation Council on Continuing Medical Education and the Nursing Continuing Education Council standards set forth by the American Nurses Credentialing Center Commission on Accreditation, continuing medical education and nursing education activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content have been asked to disclose any financial relationship* they have to a commercial interest (any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients). Such disclosure is not intended to suggest or condone bias in any presentation, but is elicited to provide participants with information that might be of potential importance to their evaluation of a given activity.
The following Activity Physician Director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content have reported the following financial interest or relationship* with various companies/organizations. The Activity Director and Planning Committee member roles were resolved by altering the individual™s control over content about the products or services of the commercial interest by the Associate Dean for CME and the Department of Medicine Chair. All potential conflict(s) were resolved.
* Kelly Kieffer, MD ~ her spouse is a consultant for OcculoBio.
* Richard I. Rothstein, MD ~ has research support from Baranova (research grant to Dartmouth-Hitchcock Medical Center) and is on the Scientific Advisory Board for Allurion.
Other planning committee member(s), speaker(s), activity director(s), author(s) or anyone in a position to control the content for this program report no financial interest or relationship* with any company(ies) or organizations whose product may be germane to the content of their presentations.
*A financial interest or relationship" refers to an equity position, receipt of royalties, consultantship, funding by a research grant, receiving honoraria for educational services elsewhere, or to any other relationship to a company that provides sufficient reason for disclosure, in keeping with the spirit of the stated policy.
Bibliographic Material
See presentation for bibliographic sources to allow for further study.
